International policy for treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) relies largely on individual patient data (IPD) from observational studies of patients treated under routine conditions. We prepared guidance on which data to collect and what measures could improve consistency and utility for future evidence-based recommendations. We highlight critical stages in data collection at which improvements to uniformity, accuracy, and completeness could add value to IPD quality. Through a repetitive development process, we suggest essential patient- and treatment-related characteristics that should be collected by prospective contributors of observational IPD in MDR/RR TB.

中文翻译：

---

改善耐多药或耐利福平的结核病治疗的患者数据质量。

国际上对耐多药和耐利福平的结核病的治疗政策（MDR / RR TB）在很大程度上取决于对常规情况下患者的观察性研究的个人患者数据（IPD）。我们准备了有关收集哪些数据以及可以采取哪些措施来改善未来基于证据的建议的一致性和实用性的指南。我们重点介绍了数据收集的关键阶段，在这些阶段中，提高一致性，准确性和完整性可以为IPD质量增加价值。通过重复的开发过程，我们建议应由MDR / RR TB的观察性IPD的潜在贡献者收集与患者和治疗相关的基本特征。